<DOC>
	<DOCNO>NCT02785731</DOCNO>
	<brief_summary>ANGLE develop Parsortix™ Cell Separation System ( Parsortix ) , automated system capable harvest rare circulate cell analysis sample peripheral blood base cellular size deformability . In small pilot study , scientist Medical University Vienna demonstrate measurement combination mRNA marker extract CTCs capture use Parsortix system could use identify woman ovarian cancer . This study design provide specimen optimization assay use clinical biomarker information ( i.e . demographic , image result and/or serum tumor marker ) combination mRNA extract rare cell blood woman present pelvic mass detection malignancy . Primary Objective : Optimization assay differentiation woman benign pelvic mass malignant pelvic mass use mRNA marker extract CTCs isolate whole blood . Multiple serum tumor marker mRNA marker measure , result compare actual clinical diagnosis make patient recognize method ( e.g . histopathology ) . The blood sample collect course study use finalize selection mRNA and/or serum tumor marker evaluate future prospective study . Exploratory Objective : Use statistical modeling determine need and/or preliminary design mathematical algorithm combine multiple serum tumor and/or mRNA marker estimation risk ovarian cancer .</brief_summary>
	<brief_title>Evaluation Multiple Biomarkers Estimate Risk Ovarian Cancer Patients With Pelvic Mass .</brief_title>
	<detailed_description>This study exploratory nature design hypothesis generate support design future study . A total 200 woman diagnose pelvic mass ( defined simple , complex solid ovarian cyst / pelvic mass ) schedule laparotomy laparoscopy removal pelvic mass enrol evaluation primary exploratory endpoint . An initial evaluation data conduct identification 15 evaluable subject histopathologically confirm ovarian cancer . It estimate 50 - 100 subject require obtain minimum 15 evaluable subject histopathologically confirm ovarian cancer . The remainder woman enrol ( expect ~100 - 150 subject ) use verify finding initial evaluation ( i.e . correlation marker absence presence malignancy ) refine assay/algorithm . Within 60 day prior surgery , subject must pelvic image study ( e.g . ultrasound , CT scan , MRI , etc . ) conduct read visualize pelvic mass accord current standard care . Results pelvic imaging study ( y ) record . Within 60 day prior , day pelvic mass surgery , collect 35mL peripheral blood one 5mL SST tube , must draw first , follow three separate 10mL EDTA tube . Serum SST tube prepare local study center use protein biomarker test . The EDTA tube ship Medical University Vienna , blood pool equal volume process use two different separation method Parsortix™ system capture harvest rare cell . The harvested material EDTA tube lysed , total RNA extract cell lysate evaluation multiple gene target use quantitative PCR ( qPCR ) . Laparotomy laparoscopy removal pelvic mass perform qualified individual . Tissue sample send local pathology department histological examination accordance standard institutional practice . Results histopathological evaluation record , include final diagnosis along histological sub-type , available , stage grade ovarian cancer disease identify . Subjects consider negative ovarian cancer : - subject undergoes surgery mass identify , ; - histopathological finding negative cancer ( i.e . benign condition ) . Subjects consider positive ovarian cancer : - histological examination tissue take time surgery confirm presence ovarian , primary peritoneal and/or fallopian tube cancer . For purpose enrollment , subject diagnose malignancy ovarian cancer well diagnose low malignant potential ( LMP ) / borderline tumor count ovarian cancer . However , two separate analysis final study data conduct : one subject diagnose cancer exclude analysis primary endpoint subject diagnose LMP / borderline tumor classify negative malignancy , second subject diagnose cancer diagnose LMP / borderline tumor classify positive malignancy . Demographical clinical data may summarize use descriptive statistic . Continuous variable may summarize use number observation , mean , standard deviation , coefficient variation , median , range appropriate . Categorical value may summarize use number observation percentage appropriate . The association marker ( i.e . serum protein marker mRNA marker ) histopathological diagnosis assess use appropriate statistical method ( e.g. , logistic regression , analysis variance [ ANOVA ] , etc . ) , depend endpoint . Analyses may perform within various histopathological diagnosis sub-groups . Other clinical covariates ( image result subject demographic ) may also include modeling . An initial evaluation correlation marker histopathological diagnosis perform identification 15 subject histopathologically verified ovarian cancer . The final cohort patient use verify finding initial evaluation ( i.e . correlation marker absence presence malignancy ) refine assay/algorithm . Bootstrap analyse may utilized entire set 200 subject finalize assay/algorithm study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Women &gt; 18 year age ; Documented evidence pelvic mass imaging ; Selected undergo laparotomy laparoscopy base find pelvic mass ( defined simple , complex solid ovarian cyst / pelvic mass ) ; Willing able provide write informed consent prior blood collection . Suitable venous access healthy enough ( determine treat physician ) provide require whole blood sample . Known pregnancy ; Subjects receive cytotoxic chemotherapy ; Previous malignancy within past 5 year , exclude skin cancer ( squamous cell basal cell ) ; Unwilling unable follow protocol requirement provide informed consent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>pelvic mass</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>gynecological cancer</keyword>
	<keyword>risk prediction</keyword>
</DOC>